Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer-Reference-Cited by-同舟云学术

Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

Published:2020-01 Issue:1 Volume:1 Page:99-111
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Anagnostou Valsamo^ORCID,Niknafs Noushin,Marrone Kristen,Bruhm Daniel C.,White James R.,Naidoo Jarushka,Hummelink Karlijn,Monkhorst Kim,Lalezari Ferry,Lanis Mara,Rosner Samuel,Reuss Joshua E.,Smith Kellie N.,Adleff Vilmos,Rodgers Kristen,Belcaid Zineb,Rhymee Lamia,Levy Benjamin,Feliciano Josephine,Hann Christine L.,Ettinger David S.,Georgiades Christos,Verde Franco,Illei Peter,Li Qing Kay,Baras Alexander S.,Gabrielson Edward,Brock Malcolm V.,Karchin Rachel^ORCID,Pardoll Drew M.,Baylin Stephen B.,Brahmer Julie R.,Scharpf Robert B.,Forde Patrick M.,Velculescu Victor E.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s43018-019-0008-8.pdf

Reference62 articles.

1. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).

2. Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clinical Oncol. 36, 633–641 (2018).

3. Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. New Eng. J. Med 378, 2093–2104 (2018).

4. Hellmann, M. D. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33, 843–852 (2018).

5. Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. New Eng. J. Med. 377, 2500–2501 (2017).

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report;Cureus;2024-09-12

3. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer;Cancer Cell;2024-09

4. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

5. Human leukocyte antigen evolutionary divergence as a novel risk factor for donor selection in acute lymphoblastic leukemia patients undergoing haploidentical hematopoietic stem cell transplantation;Frontiers in Immunology;2024-08-19